Compare Incyte Corporation (INCY) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs T-Mobile Us Inc — how do they compare? Incyte Corporation trades at $117.91 (market cap $23.11B), while T-Mobile Us Inc trades at $191.7 (market cap $211.72B). The key difference: T-Mobile Us Inc is far larger — about 9.2× Incyte Corporation's market cap, and T-Mobile Us Inc pays a 2.09% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TMUS | |
|---|---|---|
Market Cap | $23.11B | $211.72B |
Sector | Health | Media |
52-Week High | $118.52 | $259.01 |
52-Week Low | $67.38 | $167.65 |
Enterprise Value | $19.13B | $329.42B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
T-Mobile US (TMUS) trades at $195.37, up 1.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $88.3B revenue in 2025, 11.65% net margin, and consistent earnings beats in three of the last four quarters. Recent leadership changes and strategic appointments position TMUS for growth amid competitive pressures from satellite internet providers.
TMUS presents a compelling investment case with 83% analyst buy ratings and $238.40 consensus target, offering 22% upside. However, rising debt levels (39.35% debt-to-asset ratio) and Starlink competition pose significant risks. The stock's current RSI levels suggest potential near-term consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
